CSL
CSL Limited is a global biotherapy industry leader..
| EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 13 % | 2 % | 26 % | 11 % | 6 % | 7 % | 6 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 36 % | 34 % | 29 % | 32 % | 34 % | 34 % | 36 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 23 % | 21 % | 16 % | 18 % | 19 % | 20 % | 22 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 6 % | 11 % | 9 % | 10 % | - | - | - |
Source: Company filings or news article, Equity research estimates
CSL is a global biotechnology company specializing in the development and delivery of innovative biotherapies and influenza vaccines. The company serves a diverse range of clients including healthcare providers, hospitals, and governments across multiple continents such as the Americas, Asia Pacific, and Europe. Operating in the biopharmaceutical market, CSL focuses on rare and serious diseases, offering the broadest range of quality plasma-derived and recombinant therapies in the industry. The business model revolves around research and development, manufacturing, and distribution of these therapies, generating revenue through the sale of its products and services. CSL's commitment to saving lives and protecting health is evident in its extensive portfolio, which includes treatments for rare diseases, influenza vaccines, and antivenoms. The company also emphasizes diversity and inclusion within its workforce, aiming to attract the brightest and most passionate individuals from various disciplines.
Keywords: biotechnology, biotherapies, influenza vaccines, plasma-derived therapies, rare diseases, recombinant therapies, healthcare providers, global, innovation, diversity.
